Related content

Long term effects of oral sustained release morphine on neuropsychological performance in patients with chronic non-cancer pain

By Tassain V.   Attal N.   Fletcher D.   Brasseur L.   Degieux P.   Chauvin M.   Bouhassira D.  

Pain, Vol. 104, Iss. 1, 2003-07 ,pp. : 389-400

Elsevier

Access to resources Recommend Favorite

Opioids for Chronic Noncancer Pain: Still No Evidence for Superiority of Sustained‐Release Opioids

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 97, Iss. 2, 2015-02 ,pp. : 114-115

John Wiley & Sons Inc

Access to resources Recommend Favorite

Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine

By Radbruch Lukas   Lehmann K.   Gockel H.-H.   Neighbors D.   Nuyts G.  

The European Journal of Health Economics, Vol. 3, Iss. 2, 2002-06 ,pp. : 111-119

Springer Publishing Company

Access to resources Recommend Favorite

Low doses of transdermal fentanyl in opioid-naive patients with cancer pain

By Mercadante Sebastiano   Porzio Gianpiero   Ferrera Patrizia   Aielli Federica   Adile Claudio   Ficorella Corrado  

Current Medical Research and Opinion, Vol. 26, Iss. 12, 2010-12 ,pp. : 2765-2768

Informa Healthcare

Access to resources Recommend Favorite

Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain

By ÜÜberall Michael A.   Müüller-Schwefe Gerhard H.H.  

Current Medical Research and Opinion, Vol. 27, Iss. 7, 2011-07 ,pp. : 1385-1394

Informa Healthcare

Access to resources Recommend Favorite